Literature DB >> 3967610

[Persistence of antibodies against hepatitis B surface antigens after vaccination against hepatitis B].

W Jilg, M Schmidt, R Zachoval, F Deinhardt.   

Abstract

In 195 patients vaccinated against hepatitis B the course of anti-HBs concentration was followed over 4 years. Persistence of anti-HBs proved to be dependent on the level of anti-HBs concentration after basal immunization: in 14 subjects with a maximal anti-HBs level between 10 and 100 IU/l the level had dropped to less than 10 IU/l (considered to be the lowest prophylactic concentration), while 7 were anti-HBs negative. Of those who had 101-1000 IU/l after initial immunization 49% had anti-HBs levels under 10 IU/l after 4 years, while 18% were negative. Among subjects with concentrations 1001-10 000 IU/l after the third immunization only 7% had values below 10 IU/l after 4 years, 4.2% were negative. All those who, after the third immunization, had had anti-HBs levels above 10 000 IU/l, 4 years later still had anti-HBs levels of more than 100 IU/l (mean 581 IU/l). Quantitative anti-HBs determination after triple vaccination against hepatitis B thus makes it possible to predict the duration of protection and to determine the timing of re-vaccination.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3967610     DOI: 10.1055/s-2008-1068799

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  5 in total

1.  Four-year experience with a recombinant hepatitis B vaccine.

Authors:  W Jilg; M Schmidt; F Deinhardt
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

2.  Vaccination against hepatitis B--the current situation.

Authors:  W Jilg; F Deinhardt
Journal:  Infection       Date:  1986 May-Jun       Impact factor: 3.553

3.  Non-responsiveness to hepatitis-B vaccination: revaccination and immunogenetic typing.

Authors:  A Krämer; D Herth; H J von Keyserlingk; W D Ludwig; H Hampl; D Sommer; E G Hahn; E O Riecken
Journal:  Klin Wochenschr       Date:  1988-08-01

4.  Immunogenicity of a recombinant Pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster.

Authors:  B Bucher; P Francioli; B Geudelin; B Fritzell; D Lavanchy; P C Frei
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-03       Impact factor: 3.267

5.  German experimental hepatitis B vaccine--influence of variation of dosage schedule, sex and age differences on immunogenicity in health care workers.

Authors:  A Krämer; D Sommer; E G Hahn; E O Riecken
Journal:  Klin Wochenschr       Date:  1986-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.